| Ramses Luis Vega-casasnovas, MD | |
|
975 E 3rd St, Chattanooga, TN 37403-2163 | |
| (423) 778-7000 | |
| Not Available |
| Full Name | Ramses Luis Vega-casasnovas |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 975 E 3rd St, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073741369 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 076982 (Georgia) | Secondary |
| 207R00000X | Internal Medicine | 157930 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 52281 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Heartlite Hospice | Dalton, GA | Hospice |
| Erlanger Medical Center | Chattanooga, TN | Hospital |
| Murphy Medical Center Inc | Murphy, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Murphy Hospitalist Group, Pllc | 3274913637 | 19 |
| Erlanger Health | 1153780226 | 352 |
| Hospital Medicine Services Of Fl, Llc | 9234596743 | 402 |
News Archive
Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.
Gaps in the security and privacy of healthcare data still exist, even though the Health Insurance Portability & Accountability Act's (HIPAA) rules for security and privacy safeguards were extended by the Health Information Technology for Economic and Clinical Health (HITECH) Act.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
› Verified 4 days ago
| Entity Name | Henderson County Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447444559 PECOS PAC ID: 8123938115 Enrollment ID: O20040611001396 |
News Archive
Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.
Gaps in the security and privacy of healthcare data still exist, even though the Health Insurance Portability & Accountability Act's (HIPAA) rules for security and privacy safeguards were extended by the Health Information Technology for Economic and Clinical Health (HITECH) Act.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
› Verified 4 days ago
| Entity Name | Glutality Provider Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083256168 PECOS PAC ID: 9032549837 Enrollment ID: O20200825003292 |
News Archive
Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.
Gaps in the security and privacy of healthcare data still exist, even though the Health Insurance Portability & Accountability Act's (HIPAA) rules for security and privacy safeguards were extended by the Health Information Technology for Economic and Clinical Health (HITECH) Act.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
› Verified 4 days ago
| Entity Name | Murphy Hospitalist Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124768544 PECOS PAC ID: 3274913637 Enrollment ID: O20220702000087 |
News Archive
Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.
Gaps in the security and privacy of healthcare data still exist, even though the Health Insurance Portability & Accountability Act's (HIPAA) rules for security and privacy safeguards were extended by the Health Information Technology for Economic and Clinical Health (HITECH) Act.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ramses Luis Vega-casasnovas, MD 8646 Rambling Rose Dr, Ooltewah, TN 37363-7116 Ph: (336) 688-6240 | Ramses Luis Vega-casasnovas, MD 975 E 3rd St, Chattanooga, TN 37403-2163 Ph: (423) 778-7000 |
News Archive
Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.
Gaps in the security and privacy of healthcare data still exist, even though the Health Insurance Portability & Accountability Act's (HIPAA) rules for security and privacy safeguards were extended by the Health Information Technology for Economic and Clinical Health (HITECH) Act.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
› Verified 4 days ago
Dr. Pamela Rani Sud, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 725 Glenwood Drive, Suite E-500, Chattanooga, TN 37404 Phone: 423-495-2635 Fax: 423-495-2638 | |
David Shved, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5179 Fax: 423-778-2108 | |
Megan J Coylewright, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-8258 | |
Dr. Charles Robert Bosshardt, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2515 Desales Ave Ste 206, Chattanooga, TN 37404 Phone: 423-698-8101 Fax: 423-698-3450 | |
Dr. Elise Helene Marshall, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 Glenwood Dr Ste 300, Chattanooga, TN 37404 Phone: 423-495-2690 Fax: 423-495-2698 | |
Dr. Joshua Warner Hornsby, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 979 E 3rd St Ste A-440, Chattanooga, TN 37403 Phone: 423-778-2867 Fax: 423-778-2866 | |
Dr. Donald Franklin Mackler, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste. W552, Chattanooga, TN 37404 Phone: 423-629-6258 Fax: 423-629-9531 |